Cargando…

Rewiring innate and adaptive immunity with TLR9 agonist to treat osteosarcoma

BACKGROUND: Osteosarcoma (OS) is the most common primary bone tumor in children and adolescent. Surgery and multidrug chemotherapy are the standard of treatment achieving 60–70% of event-free survival for localized disease at diagnosis. However, for metastatic disease, the prognosis is dismal. Explo...

Descripción completa

Detalles Bibliográficos
Autores principales:	Cascini, Caterina, Ratti, Chiara, Botti, Laura, Parma, Beatrice, Cancila, Valeria, Salvaggio, Adriana, Meazza, Cristina, Tripodo, Claudio, Colombo, Mario P., Chiodoni, Claudia
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2023
Materias:	Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10291774/ https://www.ncbi.nlm.nih.gov/pubmed/37365634 http://dx.doi.org/10.1186/s13046-023-02731-z

Ejemplares similares

Intracellular osteopontin protects from autoimmunity-driven lymphoma development inhibiting TLR9-MYD88-STAT3 signaling
por: Rizzello, Celeste, et al.
Publicado: (2022)

The Immune Landscape of Osteosarcoma: Implications for Prognosis and Treatment Response
por: Cascini, Caterina, et al.
Publicado: (2021)

Neutrophil extracellular traps arm DC vaccination against NPM-mutant myeloproliferation
por: Tripodo, Claudio, et al.
Publicado: (2022)

Intra-tumour heterogeneity of diffuse large B-cell lymphoma involves the induction of diversified stroma-tumour interfaces
por: Sangaletti, Sabina, et al.
Publicado: (2020)

Pseudotemporal ordering of spatial lymphoid tissue microenvironment profiles trails Unclassified DLBCL at the periphery of the follicle
por: Tripodo, Claudio, et al.
Publicado: (2023)

SPARC regulation of PMN clearance protects from pristane-induced lupus and rheumatoid arthritis
por: Sangaletti, Sabina, et al.
Publicado: (2021)

Stromal niche communalities underscore the contribution of the matricellular protein SPARC to B-cell development and lymphoid malignancies
por: Sangaletti, Sabina, et al.
Publicado: (2014)

Modulation of Innate Immune Responses via Covalently Linked TLR Agonists
por: Tom, Janine K., et al.
Publicado: (2015)

HER2 Signaling and Breast Cancer Stem Cells: The Bridge behind HER2-Positive Breast Cancer Aggressiveness and Therapy Refractoriness
por: Pupa, Serenella M., et al.
Publicado: (2021)

Stimulation of Innate Immune Cells by Light-Activated TLR7/8 Agonists
por: Ryu, Keun Ah, et al.
Publicado: (2014)

Autoimmune skin inflammation is dependent on plasmacytoid dendritic cell activation by nucleic acids via TLR7 and TLR9
por: Guiducci, Cristiana, et al.
Publicado: (2010)

No Clear Clustering Dysbiosis from Salivary Microbiota Analysis by Long Sequencing Reads in Patients Affected by Oral Squamous Cell Carcinoma: A Single Center Study
por: Mauceri, Rodolfo, et al.
Publicado: (2023)

TLR Agonists as Modulators of the Innate Immune Response and Their Potential as Agents Against Infectious Disease
por: Mifsud, Edin J., et al.
Publicado: (2014)

TLR9 and STING agonists synergistically induce innate and adaptive type-II IFN
por: Temizoz, Burcu, et al.
Publicado: (2015)

WNT signaling modulates PD-L1 expression in the stem cell compartment of triple-negative breast cancer
por: Castagnoli, Lorenzo, et al.
Publicado: (2019)

Innate Immune Receptors in Human Airway Smooth Muscle Cells: Activation by TLR1/2, TLR3, TLR4, TLR7 and NOD1 Agonists
por: Månsson Kvarnhammar, Anne, et al.
Publicado: (2013)

SPARC Is a New Myeloid-Derived Suppressor Cell Marker Licensing Suppressive Activities
por: Sangaletti, Sabina, et al.
Publicado: (2019)

Light Guided In-vivo Activation of Innate Immune Cells with Photocaged TLR 2/6 Agonist
por: Ryu, Keun Ah, et al.
Publicado: (2017)

MEF2C and SOCS2 in stemness regulation
por: Vitali, Caterina, et al.
Publicado: (2015)

CD40 Activity on Mesenchymal Cells Negatively Regulates OX40L to Maintain Bone Marrow Immune Homeostasis Under Stress Conditions
por: Bassani, Barbara, et al.
Publicado: (2021)

SARS-CoV2 vertical transmission with adverse effects on the newborn revealed through integrated immunohistochemical, electron microscopy and molecular analyses of Placenta
por: Facchetti, Fabio, et al.
Publicado: (2020)

A three-gene signature marks the time to locoregional recurrence in luminal-like breast cancer
por: Chiodoni, C., et al.
Publicado: (2023)

TLR agonists enhance responsiveness of inflammatory innate immune cells in HLA-B*57-positive HIV patients
por: Dold, L., et al.
Publicado: (2020)

Carvedilol targets β-arrestins to rewire innate immunity and improve oncolytic adenoviral therapy
por: Hoare, Joseph I., et al.
Publicado: (2022)

Eicosanoids in the Innate Immune Response: TLR and Non-TLR Routes
por: Alvarez, Yolanda, et al.
Publicado: (2010)

Repurposing of the Antiepileptic Drug Levetiracetam to Restrain Neuroendocrine Prostate Cancer and Inhibit Mast Cell Support to Adenocarcinoma
por: Sulsenti, Roberta, et al.
Publicado: (2021)

Induction of Innate Immune Response by TLR3 Agonist Protects Mice against SARS-CoV-2 Infection
por: Tamir, Hadas, et al.
Publicado: (2022)

A TLR4 agonist liposome formulation effectively stimulates innate immunity and enhances protection from bacterial infection
por: Hedges, Jodi F., et al.
Publicado: (2023)

Deoxyguanosine is a TLR7 agonist
por: Davenne, Tamara, et al.
Publicado: (2019)

CD1d-dependent rewiring of lipid metabolism in macrophages regulates innate immune responses
por: Brailey, Phillip M., et al.
Publicado: (2022)

NOD2 Agonist Promotes the Production of Inflammatory Cytokines in VSMC in Synergy with TLR2 and TLR4 Agonists
por: Sun, Jinghua, et al.
Publicado: (2012)

Rewiring the cell
por: Wells, William A.
Publicado: (2004)

Ethanol, TLR3, and TLR4 Agonists Have Unique Innate Immune Responses in Neuron‐Like SH‐SY5Y and Microglia‐Like BV2
por: Lawrimore, Colleen J., et al.
Publicado: (2017)

PD‐1‐induced T cell exhaustion is controlled by a Drp1‐dependent mechanism
por: Simula, Luca, et al.
Publicado: (2021)

Breast Cancer Organoids Model Patient-Specific Response to Drug Treatment
por: Campaner, Elena, et al.
Publicado: (2020)

A Chemically Defined TLR3 Agonist with Anticancer Activity
por: Le Naour, Julie, et al.
Publicado: (2023)

Comparison of human B cell activation by TLR7 and TLR9 agonists
por: Hanten, John A, et al.
Publicado: (2008)

Specific activation of the TLR1-TLR2 heterodimer by small-molecule agonists
por: Cheng, Kui, et al.
Publicado: (2015)

Trial Watch: experimental TLR7/TLR8 agonists for oncological indications
por: Frega, Giorgio, et al.
Publicado: (2020)

Metformin: Metabolic Rewiring Faces Tumor Heterogeneity
por: Cioce, Mario, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_1e0e1uoelqcbp19tuvjqaevqmj